You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review

Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with frequent immune-related adverse events (irAEs) and is often not recommended for patients with concomitant autoimmune disease. The purpose of this systematic review is to summarize the evidence on adverse events associated with CPIs in patients with cancer and preexisting autoimmune disease.

Conclusion: Flares and irAEs in patients with autoimmune disease who are receiving CPIs can often be managed without discontinuing therapy, although some events may be severe and fatal. Prospective longitudinal studies are needed to establish incidence of adverse events and evaluate risk–benefit ratios and patient preferences in this population.

About Annals Article

Many articles published in the Annals of Internal Medicine (annals.org) offer CME credit and MOC points, earned by reading the articles and subsequently completing a multiple-choice quiz to demonstrate knowledge. Note that CME and MOC availability typically expires 3 years after article publication, but quizzes remain available to allow learners to test their knowledge.


Details

CME/MOC:

Up to 1 AMA PRA Category 1 Credits ™ and MOC Points
Expires January 2, 2020   active

Cost:

Free to Members

Format:

Journal-Based Article

Product:

Annals Article